Moderna Inc (MRNA)

[sharky]

MRNA Moderna currently has nine development candidates in its prophylactic vaccines modality, including:

Vaccines against serious respiratory infections



•
Respiratory syncytial virus (RSV) vaccine for older adults (mRNA-1777 and mRNA-1172 or V172 with Merck)



•
RSV vaccine for young children (mRNA-1345)



•
Human metapneumovirus and parainfluenza virus type 3 (hMPV/PIV3) vaccine (mRNA-1653)



•
Novel coronavirus (2019-nCoV) vaccine (mRNA-1273)



•
Influenza H7N9 (mRNA-1851)

Vaccines against serious infections transmitted from mother to baby



•
Cytomegalovirus (CMV) vaccine (mRNA-1647)



•
Zika vaccine (mRNA-1893) with the Biomedical Advanced Research and Development Authority (BARDA)

Vaccines against common viral infections with high unmet need



•
Epstein-Barr virus (EBV) vaccine (mRNA-1189)

To date, Moderna has demonstrated positive Phase 1 data readouts for six prophylactic vaccines (H10N8, H7N9, RSV, chikungunya virus, hMPV/PIV3 and CMV). Moderna’s CMV vaccine is currently in a Phase 2 dose-confirmation study. Moderna’s investigational Zika vaccine (mRNA-1893), currently in a Phase 1 study, was granted FDA Fast Track designation.

Moderna has built a fully integrated manufacturing plant in Norwood, MA which enables the promise of the technology platform.


$MRNA